Year To Quarter End Consolidated Statement Of Comprehensive Income

Carna Biosciences, Inc. - Filing #7568781

Concept 2023-01-01 to
2023-03-31
2022-01-01 to
2022-03-31
Year to quarter end consolidated statement of comprehensive income
Statement of comprehensive income
Profit (loss)
-519,210,000 JPY
-15,104,000 JPY
Other comprehensive income
Valuation difference on available-for-sale securities
-101,000 JPY
-701,000 JPY
Deferred gains or losses on hedges
-615,000 JPY
34,990,000 JPY
Foreign currency translation adjustment
1,648,000 JPY
12,206,000 JPY
Other comprehensive income
932,000 JPY
46,494,000 JPY
Comprehensive income
-518,278,000 JPY
31,390,000 JPY
Comprehensive income attributable to
Comprehensive income attributable to owners of parent
-518,278,000 JPY
31,390,000 JPY
Comprehensive income attributable to non-controlling interests
JPY
JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.